Blog
RSS FeedPosted by Michael Wonder on 26 Apr 2022
Health economic assessment of Leqvio in the treatment of high LDL cholesterol and mixed lipid disorders
26 April 2022 - The Swedish Dental and Pharmaceutical Benefits Agency has undertaken a health economic assessment of Leqvio (inclisiran) for ...
Posted by Michael Wonder on 19 Mar 2022
Final reconciliation of savings from side agreements for the full year 2021
18 March 2022 - TLV has presented the final reconciliation to the government of the outcome of the rebates in ...
Posted by Michael Wonder on 23 Feb 2022
Annual report 2021: more Government assignments and increased EU cooperation on TLV
23 February 2022 - In 2021, the Swedish Dental and Pharmaceutical Benefits Agency, TLV, reported a number of urgent government assignments ...
Posted by Michael Wonder on 22 Feb 2022
Health economic assessment of the gene therapy Libmeldy in metachromatic leukodystrophy
22 February 2022 - Within the FINOSE collaboration, TLV, together with the corresponding authorities in Finland and Norway, has produced a ...
Posted by Michael Wonder on 12 Feb 2022
Health economic assessment of Jemperli in endometrial cancer
11 February 2022 - TLV has produced a health economic assessment for the regions for the drug Jemperli (dostarlimab) which is ...
Posted by Michael Wonder on 11 Feb 2022
Health economic assessment of Adakveo for the treatment of sickle cell anaemia
11 February 2022 - Adakveo is used to prevent recurrent so-called vaso-occlusive crises in patients from 16 years of age who ...
Posted by Michael Wonder on 07 Feb 2022
Health economic assessment of Opdivo in cancer of the oesophagus or upper gastro-intestinal tract
7 February 2022 - TLV has produced a health economic assessment for the regions for Opdivo (nivolumab). ...
Posted by Michael Wonder on 03 Feb 2022
Weak krona exchange rates result in lower drug prices
3 February 2022 - The price of medicines in Sweden has fallen compared with other countries and is among the lowest ...
Posted by Michael Wonder on 27 Jan 2022
The price of cystic fibrosis drugs is still too high
27 January 2022 - The Swedish Dental and Pharmaceutical Benefits Agency, TLV, has decided that Kaftrio and Kalydeco for cystic fibrosis ...
Posted by Michael Wonder on 13 Dec 2021
Forecast 2 for the 2021 rebate from side agreements
13 December 2021 - In a new report to the government, TLV forecasts that the pharmaceutical companies will pay approximately ...
Posted by Michael Wonder on 26 Oct 2021
Evrysdi is not included in the high-cost protection
22 October 2021 - TLV assesses that the costs of using Evrysdi are too high in relation to the benefit the ...
Posted by Michael Wonder on 15 Oct 2021
TLV's web application for TNF inhibitors shows room for savings
15 October 2021 - The TLV, has developed a web application that will show the regions' use of TNF inhibitors ...
Posted by Michael Wonder on 11 Oct 2021
Health economic assessment of Poteligeo in the treatment of mycosis fungoides or Sézary syndrome
11 October 2021 - TLV has produced a health economic assessment for the regions for the drug Poteligeo (mogamulizumab). ...
Posted by Michael Wonder on 13 Sep 2021
TLV is commissioned to secure access to antibiotics
13 September 2021 - TLV, the Swedish Public Health Agency and the Medical Products Agency have been commissioned by the Government ...
Posted by Michael Wonder on 08 Sep 2021
Withdrawals from pharmaceutical benefits on 1 October 2021
8 September 2021 - Suboxone is among the medicines that will be withdrawn from the drug benefits at the companies' ...